124.3 ð©º å §ç§å°ç§èåç
ð äžææŠå¿µèªªæïŒå°ç§çé¡å€èŠçæçæ¯ 22e æ°å¢ç sepsis biomarkers (monocyte HLA-DR / MR-proADM)ãrapid diagnostics (BioFire multiplex PCR / MALDI-TOF / T2 Bacteria-Candida)ãAI-based predictor (TREWS, NEWS-2)ïŒä»¥åå°ç£ ASP å¶åºŠè source control timingãSource control æ¯å°ç§æèçé±èé¡ â åŸåŸåš case é¡è£¡èãçºä»éºŒæççŽ æäº 48 å°æéæ²éçãïŒçæ¡åžžåžžæ¯ source æ²èç (abscess æ²åŒãinfected line æ²æãnecrotic tissue æ² debride)ãèšäœèšåºååïŒSource control 6-12 å°æå § æ¯ sepsis ç ideal timingïŒè¶ææ»äº¡çè¶é«ã
124.3.0.1 ð Specialist Pearls
- Surviving Sepsis Campaign 2021: 1-hr bundle (äž)
- Antimicrobial stewardship: PCT-guided de-escalation çž®ç antibiotic 䜿çš
- Source control: drain, debride, remove infected foreign body â äžå¯ç
- Diagnostic stewardship: äžå¿ èŠç test (urinalysis on asymptomatic) â false + â é床 treat
124.3.0.2 1ïžâ£ 22E æŽæ°
- Procalcitonin (PCT): bacterial åå + 䜿çšè¿œè¹€ïŒPCT trend â â de-escalate
- CRP + PCT äžå¯å®çšå€å®; çµå clinical
- Sepsis biomarkers (æ°): monocyte HLA-DR (immunoparalysis), MR-proADM
- Rapid diagnostics: PCR multiplex (BioFire), MALDI-TOF, T2 (T2 Bacteria, T2 Candida)
- AI-based: TREWS / NEWS-2 é æž¬ sepsis
124.3.0.3 2ïžâ£ Antimicrobial Stewardship Programs (ASP) â å°ç£ context
- å¥ä¿æšå antibiotic 䜿çšå¯©æ ž
- ID consult mandatory for restricted antibiotics (vanco, carbapenem, daptomycin, polymyxin)
- é¢å § antibiogram â guide empirical
- De-escalation: å¹é€ + sensitivity åºäŸ â narrow spectrum